Twist Bioscience Co. (NASDAQ:TWST) SVP Paula Green Sells 910 Shares of Stock

Twist Bioscience Co. (NASDAQ:TWST) SVP Paula Green sold 910 shares of the stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $37.13, for a total transaction of $33,788.30. Following the sale, the senior vice president now owns 91,511 shares of the company’s stock, valued at $3,397,803.43. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Paula Green also recently made the following trade(s):

• On Tuesday, April 2nd, Paula Green sold 229 shares of Twist Bioscience stock. The shares were sold at an average price of $32.74, for a total value of $7,497.46.
• On Wednesday, March 20th, Paula Green sold 200 shares of Twist Bioscience stock. The stock was sold at an average price of $33.52, for a total value of $6,704.00.
• On Wednesday, March 6th, Paula Green sold 600 shares of Twist Bioscience stock. The shares were sold at an average price of $37.43, for a total value of $22,458.00.

Twist Bioscience Price Performance

NASDAQ:TWST traded down $1.54 during mid-day trading on Tuesday, hitting $43.13. 1,808,210 shares of the company’s stock were exchanged, compared to its average volume of 997,886. The company has a market cap of $2.51 billion, a PE ratio of -12.84 and a beta of 1.64. Twist Bioscience Co. has a one year low of $11.81 and a one year high of $44.92. The business has a fifty day moving average price of $34.11 and a 200 day moving average price of $31.34.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings results on Thursday, May 2nd. The company reported ($0.79) EPS for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.05. Twist Bioscience had a negative return on equity of 31.61% and a negative net margin of 69.24%. The firm had revenue of $75.30 million for the quarter, compared to analysts’ expectations of $70.70 million. During the same period in the previous year, the firm posted ($1.06) EPS. The business’s revenue for the quarter was up 25.1% compared to the same quarter last year. On average, equities analysts forecast that Twist Bioscience Co. will post -3.17 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on TWST shares. The Goldman Sachs Group upgraded shares of Twist Bioscience from a “neutral” rating to a “buy” rating and lifted their price target for the company from $25.00 to $45.00 in a report on Wednesday, January 17th. Barclays lifted their target price on shares of Twist Bioscience from $40.00 to $45.00 and gave the company an “overweight” rating in a research note on Friday. Robert W. Baird increased their price target on shares of Twist Bioscience from $39.00 to $40.00 and gave the stock an “outperform” rating in a research note on Friday. Evercore ISI lifted their price objective on Twist Bioscience from $46.00 to $50.00 and gave the company an “outperform” rating in a research report on Friday. Finally, Scotiabank increased their target price on Twist Bioscience from $43.00 to $48.00 and gave the stock a “sector outperform” rating in a research report on Monday. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $42.50.

Institutional Investors Weigh In On Twist Bioscience

Several hedge funds have recently added to or reduced their stakes in the stock. D.A. Davidson & CO. raised its position in shares of Twist Bioscience by 3.4% in the 4th quarter. D.A. Davidson & CO. now owns 16,774 shares of the company’s stock worth $618,000 after purchasing an additional 554 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its stake in Twist Bioscience by 96.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,470 shares of the company’s stock valued at $30,000 after purchasing an additional 721 shares in the last quarter. Teacher Retirement System of Texas raised its holdings in Twist Bioscience by 5.1% in the third quarter. Teacher Retirement System of Texas now owns 16,206 shares of the company’s stock worth $328,000 after buying an additional 790 shares during the last quarter. EdgeRock Capital LLC bought a new position in shares of Twist Bioscience in the fourth quarter worth approximately $30,000. Finally, Swiss National Bank grew its holdings in shares of Twist Bioscience by 0.8% during the first quarter. Swiss National Bank now owns 114,000 shares of the company’s stock valued at $3,911,000 after buying an additional 900 shares during the last quarter.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.